Supplementary Material – T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer
Figure S1. Patient disposition by TcellinfGEP score at data cutoff (July 30, 2018).
Figure S2. Patient disposition by PD-L1 CPS status at data cutoff (July 30, 2018).
Table S1. Baseline characteristics by TcellinfGEP score.
Table S2. Baseline characteristics by PD-L1 CPS status.
Table S3. Prevalence of TcellinfGEP and PD-L1 CPS.
Table S4. Clinical utility profile for PD-L1 CPS.